SCHEMBL9921098

SCHEMBL9921098

Cc1cc(OC/C=C(/c2ccc(Cl)cc2)c2ccc(CN3CCOCC3)cc2)ccc1CCC(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.46
PPARD Q03181 2/20 0.45
TSHR P16473 2/20 0.43
USP2 O75604 1/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
MCHR1 Q99705 1/20 0.41
KDM4E B2RXH2 1/20 0.41
CACNA1B Q00975 1/20 0.41
APBA1 Q02410 1/20 0.41
SAE1 Q9UBE0 1/20 0.41
UBA2 Q9UBT2 1/20 0.41
PTGER1 P34995 1/20 0.41
GAA P10253 1/20 0.40
HPGD P15428 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HIF1A Q16665 1/20 0.40
EPAS1 Q99814 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
HRH3 Q9Y5N1 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12160165 1.00 POLB (0.46) POLBPPARDTSHRUSP2NPC1
SCHEMBL14495856 0.87 PPARD (0.44) PPARD
SCHEMBL1745142 0.87 KDM4E (0.46) PPARDKDM4EHPGDHRH3
SCHEMBL1745143 0.87 KDM4E (0.46) PPARDKDM4EHPGDHRH3
SCHEMBL9921117 0.86 PPARD (0.49) POLBPPARDTSHRUSP2NPC1
SCHEMBL9920979 0.86 PPARD (0.49) POLBPPARDTSHRUSP2NPC1
SCHEMBL4334798 0.82 PPARD (0.61) PPARD
SCHEMBL4334801 0.82 PPARD (0.61) PPARD
SCHEMBL4325528 0.82 PPARD (0.47) PPARD
SCHEMBL12159987 0.80 PPARD (0.50) POLBPPARDMCHR1KDM4ECACNA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1979311-B1 PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS HIGH POINT PHARMACEUTICALS LLC (US) 2012-06-13 EP disclosed
EP-2386540-A1 Novel compounds, their preparation and use High Point Pharmaceuticals, LLC (US) 2011-11-16 EP disclosed
US-7943613-B2 Compounds, their preparation and use HIGH POINT PHARMACEUTICALS, LLC (US) 2011-05-17 US disclosed
US-20090093484-A1 NOVEL COMPOUNDS, THEIR PREPARATION AND USE VTVX HOLDINGS II LLC 2009-04-09 US disclosed
WO-2007071766-A2 PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS TRANSTECH PHARMA (US) 2007-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093484-A1 NOVEL COMPOUNDS, THEIR PREPARATION AND USE PPARG, PPARD, PPARA POLB 1427/4885PPARD 2/4885TSHR 1075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.